Related Experiment Video
Updated: May 14, 2026
Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019
siRNA delivery for the treatment of ovarian cancer
1Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, United States.
Abstract:
Short interfering RNAs (siRNAs) mediate the catalytic sequence-specific cleavage of target messenger RNA (mRNA) molecules, resulting in the silencing of gene products in an efficient and precise manner. One apparent application of this technology is the knockdown of genes responsible for cancer progression, including pro-proliferative oncogenes, inhibitors of apoptosis, and mediators of angiogenesis. Delivery of siRNAs into particular cells has remained the principal obstacle to the realization of the potential of RNA interference (RNAi) in the clinic. Several groups have worked to develop carriers that facilitate siRNA delivery into ovarian cancer cells in mouse models of ovarian cancer. The results have been promising, often leading to significant survival extension. Such benefit is critical for a disease that is characterized by very poor outcomes and demands novel treatment options. This review describes advancements in siRNA delivery for the treatment of ovarian cancer.
Insights
Short interfering RNAs (siRNAs) offer precise gene silencing for ovarian cancer treatment. Effective delivery systems are crucial for clinical success and improving patient survival rates.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- Short interfering RNAs (siRNAs) enable sequence-specific messenger RNA (mRNA) cleavage for gene silencing.
- siRNA technology holds promise for targeting genes driving ovarian cancer progression, such as oncogenes and angiogenesis mediators.
- Efficient siRNA delivery into target cells remains a significant challenge for clinical applications of RNA interference (RNAi).
Purpose of the Study:
- To review advancements in siRNA delivery strategies for ovarian cancer treatment.
- To highlight the potential of RNA interference (RNAi) in overcoming therapeutic resistance in ovarian cancer.
- To discuss the progress made in developing carriers for siRNA delivery in preclinical ovarian cancer models.
Main Methods:
- Review of current literature on siRNA delivery systems for ovarian cancer.
- Analysis of studies utilizing various carriers to facilitate siRNA uptake in ovarian cancer cells.
- Evaluation of the efficacy of different delivery approaches in mouse models of ovarian cancer.
Main Results:
- Promising results have been observed with various siRNA delivery carriers in preclinical ovarian cancer models.
- Significant survival extension has been reported in mouse models treated with effective siRNA delivery systems.
- The development of targeted delivery systems is key to realizing the therapeutic potential of siRNAs.
Conclusions:
- Advancements in siRNA delivery are critical for the clinical translation of RNA interference (RNAi) in ovarian cancer.
- Novel delivery strategies are essential to address the poor outcomes associated with ovarian cancer.
- siRNA-based therapies, coupled with effective delivery, represent a promising avenue for novel ovarian cancer treatments.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...